Gyre Therapeutics Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 618

Employees

  • Stock Symbol
  • GYRE

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $4.21
  • (As of Friday Closing)

Gyre Therapeutics General Information

Description

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Contact Information

Website
www.gyretx.com
Formerly Known As
Catalyst Biosciences, Catalyst Biopharmaceutical Company
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 12730 High Bluff Drive
  • Suite 250
  • San Diego, CA 92130
  • United States
+1 (858)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 12730 High Bluff Drive
  • Suite 250
  • San Diego, CA 92130
  • United States
+1 (858)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Gyre Therapeutics Stock Performance

As of 20-Nov-2026, Gyre Therapeutics’s stock price is $4.21. Its current market cap is $461M with 109M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.21 $4.52 $3.97 - $9.14 $461M 109M 179K -$0.31

Gyre Therapeutics Financials Summary

As of 30-Sep-2026, Gyre Therapeutics has a trailing 12-month revenue of $110M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 762,840 656,723 1,050,447 1,941,033
Revenue 110,058 116,588 105,757 113,450
EBITDA (24,855) 15,209 23,259 (76,895)
Net Income (29,008) 5,027 12,085 (92,933)
Total Assets 201,251 166,132 125,406 116,539
Total Debt 3,010 939 1,598 409
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gyre Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Gyre Therapeutics‘s full profile, request access.

Request a free trial

Gyre Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Gyre Therapeutics‘s full profile, request access.

Request a free trial

Gyre Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization o
Drug Discovery
San Diego, CA
618 As of 2025

Epalinges, Switzerland
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Gyre Therapeutics Competitors (82)

One of Gyre Therapeutics’s 82 competitors is ADC Therapeutics, a Formerly VC-backed company based in Epalinges, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Blueprint Medicines Formerly VC-backed Cambridge, MA
Gilead Formerly VC-backed Foster City, CA
Innate Pharma Formerly VC-backed Marseille, France
Moderna Formerly VC-backed Cambridge, MA
You’re viewing 5 of 82 competitors. Get the full list »

Gyre Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Gyre Therapeutics Investments & Acquisitions (4)

Gyre Therapeutics’s most recent deal was a Merger/Acquisition with Cullgen for . The deal was made on 04-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cullgen 04-May-2026 Merger/Acquisition Drug Discovery
Beijing Continent 30-Oct-2023 Merger/Acquisition Drug Discovery
GNI Group (F351 Program) 15-Feb-2023 Corporate Asset Purchase Buildings and Property
Targacept 20-Aug-2015 Merger/Acquisition Biotechnology
To view Gyre Therapeutics’s complete investments and acquisitions history, request access »

Gyre Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Gyre Therapeutics’s complete esg history, request access »

Gyre Therapeutics Exits (1)

Gyre Therapeutics’s most recent exit was on 30-Oct-2023 from Beijing Continent. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Beijing Continent 30-Oct-2023 Completed
To view Gyre Therapeutics’s complete exits history, request access »

Gyre Therapeutics Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Cullgen San Diego, CA 2018
Beijing Continent Beijing, China 2002

Gyre Therapeutics FAQs

  • When was Gyre Therapeutics founded?

    Gyre Therapeutics was founded in 1997.

  • Where is Gyre Therapeutics headquartered?

    Gyre Therapeutics is headquartered in San Diego, CA.

  • What is the size of Gyre Therapeutics?

    Gyre Therapeutics has 618 total employees.

  • What industry is Gyre Therapeutics in?

    Gyre Therapeutics’s primary industry is Drug Discovery.

  • Is Gyre Therapeutics a private or public company?

    Gyre Therapeutics is a Public company.

  • What is Gyre Therapeutics’s stock symbol?

    The ticker symbol for Gyre Therapeutics is GYRE.

  • What is the current stock price of Gyre Therapeutics?

    As of 20-Nov-2026 the stock price of Gyre Therapeutics is $4.21.

  • What is the current market cap of Gyre Therapeutics?

    The current market capitalization of Gyre Therapeutics is $461M.

  • What is Gyre Therapeutics’s current revenue?

    The trailing twelve month revenue for Gyre Therapeutics is $110M.

  • Who are Gyre Therapeutics’s competitors?

    ADC Therapeutics, Blueprint Medicines, Gilead, Innate Pharma, and Moderna are some of the 82 competitors of Gyre Therapeutics.

  • What is Gyre Therapeutics’s annual earnings per share (EPS)?

    Gyre Therapeutics’s EPS for 12 months was -$0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process